CUVCLINUVEL PHARMACEUTICALS LIMITED
Announcement history available from 1 August 2025
Fromto
| Date / Time | Title | Type | MS | Report Codes | |
|---|---|---|---|---|---|
| 20 Aug 2026, 19:07 | CLINUVEL Annual Results - Investor Webinar | Presentations | — | 03027, 14014 | |
| 14 Aug 2026, 18:16 | Becoming a substantial holder | Substantial Holders | — | 02001 | |
| 12 Aug 2026, 19:12 | CLINUVEL's injectable peptide platform | Company Update | — | 11001 | |
| 30 July 2026, 18:57 | Commercial update on vitiligo | Company Update | MS | 11001 | |
| 28 July 2026, 18:56 | Update - SCENESSE in vitiligo | Company Update | MS | 11001 | |
| 27 July 2026, 18:48 | Notification of cessation of securities - CUV | Other | — | 06027 | |
| 23 July 2026, 19:11 | CLINUVEL strategic reorganisation to refocus on U.S. markets | Company Update | MS | 11001, 12008 | |
| 21 July 2026, 18:35 | CLINUVEL's ADS commences trading on Nasdaq | Securities Administration | — | 14011 | |
| 20 July 2026, 18:33 | CLINUVEL's ADS to commence trading on Nasdaq | Company Administration | — | 12008, 14011 | |
| 13 July 2026, 18:34 | SCENESSE approved for EPP in Canada | Company Update | MS | 11001 | |
| 2 July 2026, 21:36 | CLINUVEL confirms terms of CEO's Employment Agreement | Company Administration | — | 12008 | |
| 16 June 2026, 19:06 | CLINUVEL publicly files 20-F to U.S. SEC | Company Administration | MS | 12008 | |
| 2 June 2026, 19:26 | CLINUVEL US Non-Deal Roadshow Presentation | Presentations | — | 03026 | |
| 7 May 2026, 21:45 | Notification regarding unquoted securities - CUV | Other | — | 06021 | |
| 28 Apr 2026, 18:50 | CLINUVEL update on Level II ADR upgrade, Nasdaq uplist | Company Administration | MS | 12008 | |
| 27 Apr 2026, 18:42 | FDA relaxes SCENESSE postmarketing requirement | Company Update | MS | 11001 | |
| 24 Apr 2026, 18:56 | Final EMA scientific advice for pivotal Phase III vitiligo | Company Update | MS | 11001 | |
| 17 Apr 2026, 19:04 | Notification of cessation of securities - CUV | Other | — | 06027 | |
| 13 Apr 2026, 18:50 | Section 708A Cleansing Statement | Securities Administration | — | 06018 | |
| 13 Apr 2026, 18:49 | Application for quotation of securities - CUV | Other | — | 06020 | |
| 13 Apr 2026, 18:18 | Change in substantial holding | Substantial Holders | — | 02002 | |
| 2 Apr 2026, 23:15 | CLINUVEL reports highlights from AAD 2026 | Company Update | — | 11001 | |
| 27 Mar 2026, 19:35 | CLINUVEL's global programs showcased at AAD | Company Update | MS | 11001 | |
| 20 Mar 2026, 19:30 | Chair Letter to Shareholders | Letters & Addresses | MS | 16002 | |
| 5 Mar 2026, 20:48 | CLINUVEL Investor Webinar Half Year Results December 2025 | Company Administration | — | 12008 | |
| 26 Feb 2026, 20:58 | Half Year Results Presentation | Financial Results | MS | 03004, 03026 | |
| 26 Feb 2026, 20:55 | CLINUVEL Record Revenues, Advances Strategic Expansion | Financial Results | MS | 03004, 03014 | |
| 26 Feb 2026, 20:54 | Appendix 4D and Half Year Report | Financial Results | MS | 03004, 03009, 03010, 03015, 03019 | |
| 19 Feb 2026, 20:04 | CLINUVEL Investor Webinar | Presentations | — | 14014 | |
| 2 Feb 2026, 19:30 | Clinical & Financial Update | Presentations | — | 03026 | |
| 15 Jan 2026, 20:11 | Managing Director Letter to Shareholders | Letters & Addresses | — | 16002 | |
| 12 Jan 2026, 19:42 | CLINUVEL - injectable peptide platform in preclinical study | Company Update | MS | 11001 | |
| 8 Jan 2026, 20:44 | SCENESSE efficacy in vitiligo - new cases presented at RDTC | Company Update | — | 11001 | |
| 2 Jan 2026, 20:22 | Notification of cessation of securities - CUV | Other | — | 06027 | |
| 19 Dec 2025, 19:34 | CLINUVEL progresses Level II ADR upgrade, Nasdaq uplist | Company Update | — | 11001, 12008 | |
| 8 Dec 2025, 19:33 | CLINUVEL expands Singapore RD&I Centre | Company Update | MS | 11001 | |
| 2 Dec 2025, 21:38 | CLINUVEL advances NEURACTHEL Instant, EU filing mid-2026 | Company Update | — | 11001 | |
| 14 Nov 2025, 19:25 | Stifel Healthcare Conference presentation | Presentations | — | 03026 | |
| 12 Nov 2025, 19:30 | Change in substantial holding | Substantial Holders | — | 02002 | |
| 3 Nov 2025, 20:51 | Update on ADR upgrade, Nasdaq uplisting | Securities Administration | — | 14011 | |
| 18 Oct 2025, 00:00 | Results of Meeting | Meetings & Governance | — | 08003 | |
| 17 Oct 2025, 23:54 | Managing Director Address | Letters & Addresses | — | 15001 | |
| 17 Oct 2025, 21:03 | Chair address | Letters & Addresses | — | 15002 | |
| 16 Oct 2025, 23:43 | Health Canada requests additional time for SCENESSE review | Company Update | — | 11001 | |
| 3 Oct 2025, 18:55 | Section 708A Cleansing Statement | Securities Administration | — | 06018 | |
| 3 Oct 2025, 18:53 | Notification of cessation of securities - CUV | Other | — | 06027 | |
| 3 Oct 2025, 18:51 | Application for quotation of securities - CUV | Other | — | 06020 | |
| 3 Oct 2025, 18:47 | Application for quotation of securities - CUV | Other | — | 06020 | |
| 1 Oct 2025, 18:32 | Management update | Company Administration | — | 12008 | |
| 29 Sept 2025, 18:36 | CLINUVEL advances new formulations in preclinical program | Company Update | MS | 11001 |
1–50 of 65
1 / 2